References

  1. Centers for Disease Control and Prevention V2. HIV/AIDS surveillance report: Diagnoses of HIV infection and AIDS in the United States and dependent areas, 2010. http://www.cdc.gov/hiv/topics/surveillance/basic.htm. Accessed September 11, 2017.
  2. Centers for Disease Control and Prevention. Fact Sheet. HIV in the United States: The Stages of Care. November 2014. https://www.cdc.gov/nchhstp/newsroom/docs/HIV-Stages-of-Care-Factsheet-508.pdf. Accessed September 11, 2017.
  3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed September 11, 2017.
  4. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(5):651-681.
  5. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: recommendations of the National Institutes of Health, the Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Diseases Society of America: April 10, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(RR-4):1-207.
  6. National HIV/AIDS Clinicians’ Consultation Center. State HIV Testing Laws. http://nccc.ucsf.edu/clinical-resources/hiv-aids-resources/state-hiv-testing-laws/. Accessed September 11, 2017.
  7. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;(55):1-17.
  8. Chou R, Selph S, Dana T, et al. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2012;157:706-718.
  9. Libman H. Screening for HIV infection: a healthy, “low-risk” 42-year-old man. JAMA. 2011;306(6):637-644.
  10. National HIV/AIDS Strategy for the United States: Updated to 2020. Federal Action Plan. December 2015. https://files.hiv.gov/s3fs-public/nhas-update.pdf. Accessed September 11, 2017.
  11. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830-839.
  12. Libman H, Fuller JD. Primary care of HIV infection. In: Libman H, Makadon HJ, eds. HIV. 3rd ed. Philadelphia: American College of Physicians; 2007.
  13. Welcome to CDC Stacks. Laboratory testing for the diagnosis of HIV infection: updated recommendations-23447. Guidelines and Recommendations. Centers for Disease Control and Prevention. https://stacks.cdc.gov/view/cdc/23447. Accessed September 11, 2017.
  14. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;(16):1119-1129.
  15. Centers for Disease Control and Prevention (CDC). 2015 STD Treatment Guidelines. https://www.cdc.gov/std/tg2015/default.htm. Accessed September 11, 2017.
  16. Kim DK, Bridges CB, Harriman KH, et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older–United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(4):91-92.
  17. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
  18. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons- Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(43):1189-1194.
  19. Whooley MA. Diagnosis and treatment of depression in adults with comorbid medical conditions: a 52-year-old man with depression. JAMA. 2012;307(17):1848-1857.
  20. Kronke K, Spitzer RL, Williams JB. The PHQ-9–validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9): 606-613.
  21. Gilead Sciences, Inc. Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2012.
  22. Andrus B, Lacaille D. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63(Pt A):2886.
  23. Choi EI, Libman H. Long-term treatment complications in HIV disease. Infectious diseases board review manual. Hosp Physician. 2007;10(Part 1):1-12.
  24. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41-47.
  25. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;1;67(1):52-58.